Core Viewpoint - Anke Biological's stock price has shown a slight decline but is expected to recover due to performance improvements and market expansion of core products, leading to a positive long-term trend [1] Group 1: Financial Performance - In the first half of 2025, Anke Biological's parent company achieved a revenue of 910 million yuan, representing a year-on-year growth of 5.13%, with the bioproducts segment growing by 7.49%, laying a solid foundation for growth in the second half [2] Group 2: Product Sales Growth - The sales of Trastuzumab (brand name: Ansaiting) are expected to see significant year-on-year growth in 2025, with sales revenue projected to exceed 100 million yuan in 2024. The product has been in a rapid market introduction phase, and its sales volume has consistently increased [3] - Anke Biological received approval for a new specification of Trastuzumab (60mg/vial), which is anticipated to enhance sales growth due to product diversification. The sales revenue for Trastuzumab in the first half of 2025 increased by 298% year-on-year [3] Group 3: Traditional Product Recovery - The sales of Yuliangqing, a traditional Chinese medicine product, are expected to see significant year-on-year growth in the second half of 2025, following a recovery after a production suspension in 2024 [4] Group 4: Hormone Product Outlook - The sales of growth hormone water injections are projected to increase year-on-year in the second half of 2025, supported by a rise in new patient enrollments and a growing proportion of water injection revenue, which now exceeds 40% of the total growth hormone product revenue [5]